CardiaMetrics

CardiaMetrics is a company established in December 2023, based in Caen and Grenoble. CardiaMetrics relies on 6 years of Research & Development of an implantable medical device for assessing cardiac function. Our goal is to market a solution that enables effective home monitoring for patients with serious illnesses such as cancer or heart failure, requiring long-term follow-up. The major challenge is to provide a solution that (1) ensures adherence without depending on patient actions to minimize the mental burden associated to the pathology, and (2) provides medical teams with intracardiac pressure variation, a reliable, actionable, and predictive biomarker for therapeutics adjustment and personalized patient care. In terms of key milestones for the next three years, CardiaMetrics aims to deploy its solution in North America and Europe, which will involve clinical investigations in 2025-2027 and obtaining FDA approval and CE certification in 2028.